Contact Us 联系我们
Contact Us 联系我们
Contact Us 联系我们

Investors

Welcome to our Investor page. Here you will find information on the latest ASX announcements, investor presentations and other shareholder information on Race Oncology.

Race Oncology

Race Oncology is a specialty pharmaceutical company focused on rediscovering and rescuing life-saving drugs that can deliver early commercial milestones. Race Oncology’s first asset is Bisantrene, a small molecule Chemotherapy drug that has been evaluated clinically for Acute Myeloid Leukaemia (AML).

ASX Announcements



DateTitle
24/12/2018Change in substantial holdingDownload
24/12/2018Change in Director's Interest Notice-Peter MolloyDownload
24/12/2018Change in substantial holdingDownload
24/12/2018Change of Director's Interest Notice-Dr William GarnerDownload
21/12/2018Cleansing NoticeDownload
21/12/2018Appendix 3BDownload
17/12/2018Race signs agreement for Bisantrene NPP in IsraelDownload
13/12/2018Change in substantial holdingDownload
13/12/2018Change of Director's Interest Notice-Dr William GarnerDownload
27/11/2018Appendix 3BDownload
1  2  3  4  5  6  7  8  9  10  11  12  

ASX: RAC

Price

Latest News

Read All Stories

Don't miss important updates

Get the latest news & announcement and stay up-to-date.

© 2018 Race Oncology. Website By Multiplier